➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Dow
Boehringer Ingelheim
AstraZeneca
McKinsey
Harvard Business School

Last Updated: September 25, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,461,187


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,461,187 protect, and when does it expire?

Patent 8,461,187 protects DEXILANT and DEXILANT SOLUTAB and is included in two NDAs.

Protection for DEXILANT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eight patent family members in five countries.

Summary for Patent: 8,461,187
Title:Multiple PPI dosage form
Abstract: Herein provided are dosage forms (variously referred to as "formulations") comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.
Inventor(s): Taneja; Rajneesh (Libertyville, IL), Vakilynejad; Majid (Pleasant Prarie, WI)
Assignee: Takeda Pharmaceuticals U.S.A., Inc. (Deerfield, IL)
Application Number:11/629,016
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,461,187
Patent Claim Types:
see list of patent claims
Dosage form; Use;

Drugs Protected by US Patent 8,461,187

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa DEXILANT dexlansoprazole CAPSULE, DELAYED RELEASE;ORAL 022287-001 Jan 30, 2009 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Takeda Pharms Usa DEXILANT dexlansoprazole CAPSULE, DELAYED RELEASE;ORAL 022287-002 Jan 30, 2009 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Takeda Pharms Usa DEXILANT SOLUTAB dexlansoprazole TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL 208056-001 Jan 26, 2016 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,461,187

PCT Information
PCT FiledJune 01, 2005PCT Application Number:PCT/US2005/019028
PCT Publication Date:January 26, 2006PCT Publication Number: WO2006/009602

International Family Members for US Patent 8,461,187

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005264864 ⤷  Try it Free
Canada 2570916 ⤷  Try it Free
European Patent Office 1768668 ⤷  Try it Free
Japan 2008503455 ⤷  Try it Free
Japan 2014193888 ⤷  Try it Free
Japan 5563735 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
McKesson
Johnson and Johnson
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.